| 标题： | mTOR抑制剂西罗莫司治疗免疫性血液病中国专家共识 |
| title： | Chinese expert consensus on the mTOR inhibitor sirolimus for the treatment of immune hematologic diseases |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 临床医生 |
| Guide users： | clinician |
| 证据分级方法： | Grade 分级 |
| Evidence grading method： | grade classfication |
| 制定单位： | 陆军军医大学第二附属医院 |
| Formulating unit： | The Second Affiliated Hospital of the Army Medical University |
| 注册时间： | 2024-06-21 |
| Registration time： | |
| 注册编号： | PREPARE-2024CN856 |
| Registration number： | |
| 指南制订的目的： | 针对难治性免疫性血液病的治疗瓶颈，目前众多药物的有限性，以及mTOR抑制剂在免疫性疾病治疗方面的优势，提高中国免疫性血液病的治疗水平，促进临床实践标准化，以帮助临床医生更精准的治疗免疫性血液病，特别是优化使用mTOR抑制剂治疗免疫性血液病。 |
| Purpose of the guideline： | To address the therapeutic bottleneck of refractory immune hematologic diseases, the limited availability of many current drugs, and the advantages of mTOR inhibitors in the treatment of immune disorders, to improve the treatment of immune hematologic diseases in China, and to promote the standardization of clinical practice in order to help clinicians to treat immune hematologic diseases more accurately and, in particular, to optimize the use of mTOR inhibitors in the treatment of immune hematologic diseases. |
